Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
This activity is supported by an educational grant from Amgen.
Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy that continues to pose challenges for patients and oncologists alike. The foundation for the use of targeted therapies in the treatment of this disorder continues to grow, with new options such as bispecific T-cell engagers, CAR-T therapy, and antibody-drug conjugates shaping the treatment paradigm. While these treatment options have the potential to improve outcomes for your patients, they also present new challenges with respect to assessment of the safety and efficacy of new therapies and development of optimal strategies to incorporate them, when appropriate. Through a combination of didactic presentation and lively discussion, our panel of experts in the management of patients with ALL will cover a wide range of topics to help you meet these challenges. You will gain expert perspectives on key data from clinical studies in ALL, the implications of minimal residual disease (MRD) assessment, and the therapeutic implications of recent and ongoing studies.
By participating in this exciting program, you will learn about:
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists, hematologists, and fellows who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.
Upon completion of this activity, you should be better prepared to:
Elias Jabbour, MD
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/Research Support: Amgen, Pfizer, Takeda, Adaptive Biotechnologies, Novartis, Spectrum, AbbVie, Bristol-Myers Squibb
Marcos de Lima, MD
Professor of Medicine
Case Western Reserve University School of Medicine
Director, Hematologic Malignancies and Stem Cell Transplant Program
University Hospitals Seidman Cancer Center
Disclosure: Grant/Research Support: Celgene; Consultant: Celgene, Pfizer
Jae H. Park, MD
Assistant Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Consultant: Amgen, Novartis, Adaptive Biotechnologies
José María Ribera, MD
Associate Professor in Medicine
Autonomous University of Barcelona
Head, Clinical Hematology
Catalan Institute of Oncology at HUGTP in Badalona
Director, Stem Cell Transplantation Unit, HUGTP
Disclosure: Grant/Research Support: Amgen, Pfizer, Shire; Consultant: Amgen, Pfizer, Shireies
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
PER Pulse™ Recaps
1 of 3
PER Pulse™ Recap
Overview of Recent Advancements in ALL and Emerging Therapeutics in the Frontline Setting
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy that continues to pose therapeutic challenges for patients and oncologists alike. Although pediatric ALL has a cure rate of ≥80% with the use of risk-directed therapy, outcomes among adult patients with these strategies have yielded lower rates of success. Several factors may account for this difference, and in this activity, Dr. Elias Jabbour addresses not only some of the key tumor features that may account for differences in outcomes, but also some of the new therapies that may help to shape treatment of patients with ALL in the frontline and salvage settings.
In addition, Dr. José María Ribera and other members of our expert panel discuss the latest therapeutic implications of different subtypes of ALL in the frontline setting, as well as the role of minimal residual disease assessment in guiding therapeutic selections. Dr. Ribera and the panel also present ALL treatment options for different age groups, including a case-based discussion.
2 of 3
PER Pulse™ Recap
Relapsed/Refractory ALL Advancements and Considerations for CAR-T Therapy in ALL
In this activity, Dr. Elias Jabbour and our panelists address several topics, including the treatment of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Historical standards of care for these patients are reviewed, as well as how the treatment paradigm is evolving with the incorporation of new therapies, such as bispecific T-cell engager therapy and antibody-drug conjugate therapy. Recent studies are explored and assessed, and the faculty provide key insights into the management of patients with R/R ALL with another case-based discussion.
In addition, Dr. Jae Park and the panel discuss clinical evidence pertaining to the use of CAR T-cell therapy in patients with ALL. Studies in pediatric and adult patients with ALL are reviewed, as the faculty address safety and efficacy data of current therapies and new platforms. A case-based discussion highlights key points regarding treatment selection for patients who may be candidates for CAR T-cell therapy.
3 of 3
PER Pulse™ Recap
Considerations for Transplant Therapy in ALL and Future Therapeutic Directions
As a key component of this activity, Dr. Marcos de Lima and the faculty present additional considerations for incorporating stem cell transplantation into the treatment of patients with acute lymphoblastic leukemia (ALL), including real-world clinical issues that oncologists may face in the management of these patients, such as posttransplant maintenance strategies.
In addition, Dr. Elias Jabbour provides a brief summary of the role of bispecific T-cell engagers in the management of patients with ALL, as well as a look toward active areas of investigation for this treatment modality in other hematologic malignancies, such as relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and acute myeloid leukemia.
Please use the form below to Register or Log In to begin Activity.
April 10, 2019
April 10, 2019
ONS: Working Group to Optimize Outcomes in Myelofibrosis and Polycythemia Vera: Real-World Applications for Nurses
April 12, 2019
ONS: Optimizing Outcomes in Melanoma with BRAF/MEK Inhibitor and Immunotherapeutic Strategies: Essentials for the Onco-Nurse
April 12, 2019
ONS: Recognizing and Treating Oncologic Emergencies in the Cancer Patient: What Does the Nurse Need to Know?
April 12, 2019
Apr 30, 2019